$XAIR News

Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026

Beyond Air Affirms FY2027 Sales Guidance of $16.000M-$18.000M vs $16.715M Est

Beyond Air Reports Q2 Preliminary Revenue Of ~$2.3M, Reiterates FY26 Revenue Range $16M - $18M

Beyond Air New US Patent App #20260284331 Published Today For "METHODS EMPLOYING GASEOUS NITRIC OXIDE FOR INHIBITING TUMOR GROWTH".

Lake Street Initiates Coverage On Beyond Air with Buy Rating, Announces Price Target of $10

Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

Beyond Air Receives FDA's Breakthrough Device Designation To LungFit GO To Treat Nontuberculous Mycobacterial Pulmonary Disease

Beyond Air Has Been Granted Australian Patent Number 2020228618 Titled "System and method for delivery of gas to a tissue (for treatment of tumors)"

Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments

Beyond Air Signs Agreement With UNIVO For NeuroNOS Stake Sale; Receives 19.99% UNIVO Equity And $0.01 Warrants

Beyond Air (XAIR) Q1 2027 Earnings Call Transcript

Beyond Air Inc (XAIR) (Q1 2027) Earnings Call Highlights: Strategic Financing and Pipeline ...

Beyond Air, Inc. (XAIR) Q1 2027 Earnings Call Transcript

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

Beyond Air Q1 EPS $(11.00) Misses $(9.40) Estimate, Sales $1.768M Miss $1.929M Estimate

Beyond Air Affirms FY2027 Sales Guidance of $16.000M-$18.000M vs $9.137M Est

Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026

Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

Beyond Air, Inc. Q4 2026 Earnings Call Summary

Beyond Air (XAIR) Q4 2026 Earnings Call Transcript